Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06905132 · ClinicalTrials.gov registry record · Phase 2

Preoperative 5-Day Radiotherapy for Soft Tissue Sarcoma

A Phase 2 study of Soft Tissue Sarcoma, sponsored by Medical University of South Carolina.

Recruiting
Registry status
Phase 2
Development phase
40
Enrollment target
1
Study location

NCT06905132: Recruiting Phase 2 study of Soft Tissue Sarcoma, sponsored by Medical University of South Carolina.

NCT06905132 is a Phase 2 study of Soft Tissue Sarcoma that is actively recruiting participants, run by Medical University of South Carolina. The registered enrollment target is 40 participants, below the 78-participant average among 55 other Soft Tissue Sarcoma trials with a reported enrollment target (49% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06905132, a Phase 2 study of Soft Tissue Sarcoma, is actively recruiting participants, sponsored by Medical University of South Carolina.

RECRUITING
Registry status
Phase 2
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research study is to preserve healthy tissue around the cancer on the arm(s) and/or leg(s) using Hypofractionated radiotherapy, while treating the cancer and preventing it from spreading to other areas of the body.

Primary Outcome

Evaluate the safety of 5-day HFRT as measured by the rates of major wound complications occurring within 120 days of surgery.

Conditions Studied

Interventions

  • RADIATION Hypofractionated Radiation Therapy

Study Locations (1)

South Carolina

  • Medical University of South Carolina - Charleston

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2025-04-01
Est. Completion 2027-03-31
Phase Phase 2

What NCT06905132 shows while recruiting

NCT06905132 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 78-participant average among 55 other Soft Tissue Sarcoma trials with a reported enrollment target (49% lower).

The record links to 1 condition, with Soft Tissue Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which Hypofractionated Radiation Therapy is the first listed.

NCT06905132 reports a single indexed study location in South Carolina.

Frequently Asked Questions

What is clinical trial NCT06905132 about?

NCT06905132 is a clinical study titled "Preoperative 5-Day Radiotherapy for Soft Tissue Sarcoma". The purpose of this research study is to preserve healthy tissue around the cancer on the arm(s) and/or leg(s) using Hypofractionated radiotherapy, while treating the cancer and preventing it from spreading to other areas of the body.

What is the current status of trial NCT06905132?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-04-01. Estimated completion is 2027-03-31.

What conditions does trial NCT06905132 study?

This clinical trial studies the following conditions: Soft Tissue Sarcoma.

What interventions are being tested in trial NCT06905132?

The interventions under investigation include: Hypofractionated Radiation Therapy (RADIATION).

Who is sponsoring clinical trial NCT06905132?

This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06905132 being conducted?

This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Soft Tissue Sarcoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06905132's enrollment target sits among peer trials

40 27th of 55 higher than 24 of 55 other Soft Tissue Sarcoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Soft Tissue Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06905132, the US trial registry maintained by the National Library of Medicine. NCT06905132 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.